CMS keeps Medicare drug caps, counts taxes and vaccine fees

For people filling selected drugs in Medicare Part D, the price at the counter would still come with a federal ceiling. In Washington, CMS says the negotiated price for those medicines could not exceed the applicable maximum fair price, or MFP, plus dispensing fees. The proposal would also fold sales tax and vaccine administration fees into the payment definition, with the new language starting in 2029.

Part D is Medicare’s prescription drug benefit, and the details matter because they affect how plans and pharmacies are paid for certain medicines. The agency is not just naming a number. It is defining what can sit on top of that number.

What sits on top of the cap

The practical question behind the rule is simple: when a drug is negotiated, what else counts as part of the bill? CMS would answer that directly by adding sales tax and vaccine administration fees to the definition.

Even with those items included, the core limit stays in place. For selected drugs, the negotiated price must remain at or below the MFP plus dispensing fees. That gives plans, pharmacies and manufacturers a clearer line to work from when the program applies to a covered medicine.

The 2029 line in the sand

CMS says the revised definition would apply beginning in 2029. Until then, the proposal leaves the current structure in place, but it signals how the agency wants the negotiation program to count costs once the new framework kicks in.